Tn order to assess the impact of the recent upsurge in pediatric drug research, the 1980 edition of the Physicians Desk Reference was reviewed for data and indications pertaining to pediatric and obstetric usage. A total of 1.133 entries were reviewed. Of these 71.9% were oral preparations, 20% parenteral, 1.6% various other routes of administration and 6.5% included multiple routes. Dosing data based on weight or surface area was provided in 27.8% of entries. Specific pediatric dosing data was provided in 40.9% of entries while pediatric usage was specifically contraindicated in 8.9% of entries. In 39.1% of entries no mention was made of pediatric usage and in 11.1% it was mentioned, but without clear recommendations or data. In 2.6% of entries use in pregnancy was approved while 10.3% contained a definite contraindication for such use. The remaining entries either failed to mention use in pregnancy (31.8%) or mentioned use in pregnancy but without definite recommendation (55.3%). Use in breast feeding mothers was mentioned in 27.9% of entries with data provided in 107 entries and a definite contraindication in 104. Data on overdose management was provided in 29.8% of entries. Marked variability was noted between drug classes and manufacturers in terms of the information provided. It is clear from the above analysis that a continued emphasis is needed by manufacturers on providing solid data pertaining to drug usage in pediatrics and obstetrics. York. Butorphanol (B), a new synthetic agonist-antagonist type analgesic, was evaluated in 34 patients aged 4-12 years requiring a parenteral medication for relief of pain following elective surgical procedures. B was administered IM when, in the estimate of the patient or the recovery room staff, an analgesic was required. Doses of B ranged from 0.01 mglkg to 0.02 mglkg, with most patients receiving 0.015 mglkg. Scores of pain intensity (0-3) and relief (0-4) were done prior to dosing and at hourly intervals for six hours following the dose, or until additional medication was required. Surgery inoluded orthopedic (12), abdominal (5))noncardiac thoracic ( 3 ) ) genitourinary (11) and miscellaneous (2) procedures. There were 19 male and 15 female patients. 16/34 patiems continued to experience good pain relief at the end of the six hour observation period. The mean length of time to remedication was 5.0 hr. with a 6 hr. maximum given. The range was 2-6 hr. At any given dose, pain relief tended to be better and more prolonged in the younger patients. This may derive from the increased sedation seen with B in the younger children. There was no significant difference between the three doses used in degree or duration of analgesic effect. Except for one patient who experienced transient urinary retention, sedation was the only significant side effect seen. This is the first reported dose ranging study of pain therapy in children. B, at a dose of 0.01-0.02 mglkg, provided good relief of post-operative pain in children. . . -60-hydr~x~cbrtisol (~~oHF), a normally occurring polar metabolite of cortisol has been shown to be a sensitive index forhepatic enzyme induction. 6BOHF is formed by the mixed function midase system in the liver and excreted by the kidney. Pb is known to inhibit hepatic microsomal activity. In order to measure inhib-. itory effects of lead on drug metabolizing enzyme activity 60OHF excretion was measured in 11 children (age 2-9 yrs) with mild to moderate Pb intoxication (nl renal function) prior to chelation therapy. Correlations were examined between 680HF and blood Pb, erythrocyte protoporphyrin (EP) and urinary Pb excretion (after a CaNa2EDTA provocative test). 60OHF excretion in normal controls was 0.23 %03 mg/m2/24h, but excretion in Pb burdened children was reduced to 0.17 f 2 mg/m2/24h; (pC.01). There was a highly significant correlation between 6 80HF and EP, mean 173220!~g/dl (r=-0.7 3 pC.01) and 6BOHF and urinary Pb, mean 8162134pg124h (r=-0.85 pC.001) but none between blood Pb, mean 45.2?11.5ug/dl, and 60OHF (p>0.2). The correlation between 17-hydroxycorticoid excretion and EP or urinary Pb was not significant. Conclusions: 1) The data show that children with undue Pb absorption may have decreased 680HF excretion; 2) 600HF may thus serve as a noninvasive probe to assess the chelatable, potentially toxic, fraction of body Pb stores; 3) 600HF may also be used as a noninvasive index to evaluate the inhibitory effects of undue Pb absorption on drug metabolizing enzyme activity.
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